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Abstract 
      This study composed of two parts, the first one a survey and the 
other one is experiment to estimate some lipids values among 
hypothyroidism and sub clinical hypothyroid females compared to 
euothyroid group. A survey was carried out for records of thyroid 
function test from the Radio Immuno Assay (RIA) laboratories in Sudan 
Atomic Energy Commission (SAEC). This was during the period from 
1994-1996; the purpose was to explore the ratio of males to females, 
mean of their ages and the prevalence of hypothyroid function among 
them. About (4268) subjects visited the lab for thyroid function test 
(TFT), (3730) of them were found to be females while males were only 
about (538).  Mean of their ages ranging between 30-50 years. 
    For the experiment part, one hundred and twenty females were 
selected to participate in this study, were divided into three equal groups 
as hypothyroidism, sub clinical hypothyroidism cases and a third group of 
euothyroid individuals was used as control. The levels of some serum 
lipids were measured (cholesterol, TG, LDL and HDL).The effect of 
thyroid hypo function on lipid was as follows:  
1/ the hypothyroidism group showed highly significant levels of 
serum cholesterol, LDL –cholesterol and TG. 
2/ Serum cholesterol and LDL –cholesterol levels in group with 
sub clinical hypothyroidism slightly elevated, in comparison 
with euothyroid group that represented normal values of these fractions. 
In the present work a clear effect of the thyroid hormones levels 
was observed. The serum lipids values were influenced this was showed 
(p<0.0) as significant increase of the total cholesterol and LDL-
cholesterol values in hypothyroid females. 
 
  ﺑﺴﻢ اﷲ اﻟﺮﺣﻤﻦ اﻟﺮﺣﻴﻢ
 ﻣﻠﺨﺺ اﻟﺪراﺳﺔ
     ﻟﻤﻌﺭﻓـﺔ    ﺘﺠﺭﺒﺔ   ﻭﺍﻵﺨﺭ  ﺍﺤﺼﺎﺌﻰ ﻤﺴﺢ   ﺍﻷﻭل  ﺠﺯﺀﻴﻥ، ﻤﻥ  ﻤﺘﻜﻭﻨﺔ ﺴﺔ ﺍﻟﺩﺭﺍ  ﻫﺫﻩ
 )msidioryhtopyhﻘﺹ ﻓﻲ ﻫﺭﻤﻭﻥ ﺍﻟﻐﺩﺓ ﺍﻟﺩﺭﻗﻴﺔ  ﻟﺩﻴﻬﻥ ﻨ ﺇﻨﺎﺙ  ﺒﻴﻥ ﺍﻷﺠﺯﺍﺀ ﺍﻟﺩﻫﻨﻴﺔ  ﺒﻌﺽ ﻗﻴﻡ
 ﻟﺩﻴﻬﺎ ﻤﺴﺘﻭﻯ ﻁﺒﻴﻌـﻲ ﻤﺠﻤﻭﻋﺔﻤﻘﺎﺭﻨﺔ ﺒ  )msidioryhtopyh lacinilc bus( ﻟﺩﻴﻬﻥ ﻭﺇﻨﺎﺙ (
  .dioryhtoue( )ﻤﻥ ﺍﻟﻬﺭﻤﻭﻥ
 ﻓﻲ (AIR ) ﺒﻤﻌﺎﻤل ﺍﻟﻘﻴﺎﺱ ﺍﻹﺸﻌﺎﻋﻲ ﺍﻟﻤﻨﺎﻋﻲ  ﺍﻟﺩﺭﻗﹼﻴﺔ  ﺍﻟﻐﺩﺓ ﻭﻅﻴﻔﺔ ﻓﺤﺹ ﻤﺴﺢ ﻨﻔﹼﺫ ﻟﺴﺠﻼﺕ ﺍﻟ
؛ ﺍﻟﻐـﺭﺽ 6991 - ﻡ 4991 ﺃﺜﻨﺎﺀ ﺍﻟﻔﺘﺭﺓ ﻤـﻥ ﻭﺫﻟﻙ )CEAS( ﻴﺔﻁﺎﻗﺔ ﺍﻟﺫﺭﻴﺔ ﺍﻟﺴﻭﺩﺍﻨ ﻫﻴﺌﺔ ﺍﻟ 
ﺒﻠﻎ ﻋﺩﺩ ﺍﻟﺫﻴﻥ  . ﺒﻴﻨﻬﻡ ﻭﺍﻨﺘﺸﺎﺭ ﻨﻘﺹ ﺍﻟﻬﺭﻤﻭﻥ  ﻨﺴﺒﺔ ﺍﻟﺫﻜﻭﺭ ﺇﻟﻰ ﺍﻹﻨﺎﺙ، ﻤﺘﻭﺴﻁ ﺃﻋﻤﺎﺭﻫﻡ ﻤﻌﺭﻓﺔ
ﺒﻴﻨﻤﺎ ﺍﻟـﺫﻜﻭﺭ ( 0373)ﻲ ﻟﺍ ﺍﻹﻨﺎﺙ ﺤﻭ  ﺒﻠﻎ ﻋﺩﺩ (8624 )ﻲﻟﺍﺤﻭﻓﻲ ﺘﻠﻙ ﺍﻟﻔﺘﺭﺓ  ﺯﺍﺭﻭﺍ ﺍﻟﻤﻌﺎﻤل 
  .ﺴﻨﺔ 05 -02ﺡ ﺒﻴﻥ  ﺘﺭﺍﻭﺍﻷﻋﻤﺎﺭ ﻤﺘﻭﺴﻁ( 835)ﻜﺎﻨﻭﺍ ﻓﻘﻁ ﺤﻭﺍﻟﻲ 
 ﻟﻠﻤﺸﺎﺭﻜﺔ ﻓﻲ ﻫـﺫﻩ ﺍﻟﺩﺭﺍﺴـﺔ، ﺍﺨﺘﺭﻥ ﺃﻨﺜﻰ ﻥﻤﺎﺌﺔ ﻭﻋﺸﺭﻭ ،  ﻤﻥ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﺘﺠﺭﻴﺒﻲﺠﺯﺀ  ﺍﻟ ﻓﻲ 
ﻤﺠﻤﻭﻋﺔ ﻟﺩﻴﻬﺎ ﻨﻘﺹ  ,  ﻟﺩﻴﻬﺎ ﻨﻘﺹ ﻓﻲ ﺍﻟﻬﺭﻤﻭﻥ  ﺜﻼﺜﺔ ﻤﺠﻤﻭﻋﺎﺕ ﻤﺘﺴﺎﻭﻴﺔ ﻤﺠﻤﻭﻋﺔ ﺇﻟﻲ ﻥﻗﺴﻤ
 ﺩﻤﺕﺨﺍﺴـﺘ ﺘﺤﺕ ﺴﺭﻴﺭﻱ ﻓﻲ ﺍﻟﻬﺭﻤﻭﻥ ﻭﻤﺠﻤﻭﻋﺔ ﺜﺎﻟﺜﺔ ﻟﺩﻴﻬﺎ ﻨﺴﺒﺔ ﻁﺒﻴﻌﻴـﺔ ﻤـﻥ ﺍﻟﻬﺭﻤـﻭﻥ 
 ,GT ,loretselohc() ﺘﻡ ﻗﻴﺎﺱ ﻤﺴﺘﻭﻱ ﺒﻌﺽ ﻤﻥ ﺍﻻﺠﺯﺍﺀ ﺍﻟﺩﻫﻨﻴـﺔ ﻓـﻲ ﺍﻟـﺴﻴﺭﻡ .ﻴﻁﺭﺓﻜﺴ
  LDH dna LDL
  :ﻗﻴﺔ ﻋﻠﻰ ﻫﺫﻩ ﺍﻻﺠﺯﺍﺀ ﺍﻟﺩﻫﻨﻴﺔ ﺠﺎﺀ ﻜﻤﺎ ﻴﻠﻲ ﻨﻘﺹ ﻫﺭﻤﻭﻥ ﺍﻟﻐﺩﺓ ﺍﻟﺩﺭﺘﺄﺜﻴﺭ
  ﻤـﻥ  ﺫﺍﺕ ﻤﻌﻨـﻲ ﺃﻅﻬﺭﺕ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﺘﻲ ﻟﺩﻴﻬﺎ ﻨﻘﺹ ﻓﻲ ﺍﻟﻬﺭﻤﻭﻥ ﻤﺴﺘﻭﻴﺎﺕ ﻤﺭﺘﻔﻌﺔ  -1
  .GT dna loretselohc -LDL ,loretselohc
ﻠﻤﺠﻤﻭﻋﺔ ﺍﻟﺘﻰ ﻟﺩﻴﻬﺎ ﻓﻲ ﺍﻟﺴﻴﺭﻡ  ﻟ loretselohc – LDL dna loretselohc  ﻱﻤﺴﺘﻭ -2
ﻤﻘﺎﺭﻨﺔ ﺒﺎﻟﻤﺠﻤﻭﻋـﺔ , ﺍﺕ ﻤﻌﻨﻲ ﻨﻘﺹ ﺘﺤﺕ ﺴﺭﻴﺭﻯ ﻓﻲ ﺍﻟﻬﺭﻤﻭﻥ ﻨﺴﺒﺔ ﻤﺭﺘﻔﻌﺔ ﻗﻠﻴﻼ ﺫ 
ﺍﻟﺘﻲ ﺍﻅﻬﺭﺕ ﻤﺴﺘﻭﻴﺎﺕ ﻁﺒﻴﻌﻴﺔ ﻓﻲ ﻫﺫﻩ ﺍﻻﺠـﺯﺍﺀ ﻟﺩﻴﻬﺎ ﻨﺴﺒﺔ ﻁﺒﻴﻌﻴﺔ ﻤﻥ ﺍﻟﻬﺭﻤﻭﻥ  ﺍﻟﺘﻲ
  .ﺍﻟﺩﻫﻨﻴﺔ 
 ﻗﻴﻡ ﺍﻟﺩﻫﻭﻥ ﻓـﻲ .ﺜﻴﺭ ﻭﺍﻀﺢ ﻟﻤﺴﺘﻭﻱ ﺍﻟﻬﺭﻤﻭﻥ ﻗﺩ ﻟﻭﺤﻅ ﺎﻓﻲ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﺤﺎﻟﻴﺔ ﺘ             
 -LDL dna loretselohCﺘﺎﺜﺭﺕ ﺤﻴﺙ ﻜﺎﻨﺕ ﻫﻨﺎﻙ ﺯﻴﺎﺩﺓ ﻤﻌﻨﻭﻴﺔ ﻓـﻲ ﻤـﺴﺘﻭﻱ  ﺍﻟﺴﻴﺭﻡ
  . ﺒﻴﻥ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﺘﻲ ﻟﺩﻴﻬﺎ ﻨﻘﺹ ﻓﻰ ﺍﻟﻬﺭﻤﻭﻥloretselohc
  
 
Table of Contents 
 Page
Acknowledgement  I 
Abstract  ii 
Abstract (Arabic) iii 
Table of contents  iv 
List of Tables vii 
List of Figures viii 
 
Introduction 1 
 
Chapter One Literature Review 
 
1.1    Thyroid gland:                                                                   4 
1.1.2 Thyroid hormones:                                                            4 
1.1.3  Relation of Iodine to thyroid function                            6 
1.1.4  Action of thyroid hormones                                              7 
1.1.5  Control of thyroid function                                              9 
1.1.6  Abnormalities in thyroid function                                  9 
1.2.1  Hypothyroidism 10 
1.2.2  Etiology & incidence of hypothyroidism: 10 
1.2.3  Symptoms of hypothyroidism 12 
1.3     Sub clinical Hypothyroidism 13 
1.3.1   Causes                                                                                       13 
1.3.2   Clinical Implications:                                                               13 
1.4     The Plasma lipids                                                                14 
1.4.1  Cholesterol Metabolism                                                
 
15 
1.4.2 Low Density Lipoproteins                                               15 
1.4.3 High Density Lipoproteins, HDL                                     16 
1.5    Hyperlipidemia and Hypothyroidism                                   18 
 
Chapter Two Material and Methods 
 
20 
2.1.The survey 21 
2.2. Subjects 21 
2.3. Samples and sampling techniques 21 
2.4. Laboratory methods  22 
2.4.1. Radio immuno assay (RIA)  22 
2.4.1.1. T4 kit  22 
2.4.1.2. T3 kit 22 
2.4.1.3. Thyroid stimulating hormone (TSH) kit 23 
2.4.1.4. T4 assay procedure  23 
2.4.1.5. T3  assay 24 
2.4.1.6. TSH assay 24 
2.4.2. Estimation of Serum Lipids 26 
2.4.2.1. Estimation of Total Cholesterol 26 
2.4.2.2. Estimation of High- density Lipoprotein Cholesterol 
             (HDL-C) 
28 
2.4.2.3. Estimation of Low- density Lipoprotein Cholesterol  
(LDL-C): 
29 
2.4.2.4. Estimation of Triglycerides 31 
2.5 Statistical analysis  33 
 
 
Chapter Three Results 
 
 
 
 
34 
3-1 The survey  35 
3.1.1 Statistical analysis of subjects who referred to the RIA 
laboratory, of SAEC (1994-1996):                                                    
35 
3.2 Thyroid function test status in the study group of Sudanese 
females:                                                                                               
43 
3.3 Serum Lipid profiles results:                                                        52 
3.3.1Triglycerides (TG) level among study groups:                       52 
3.3.2 Total cholesterol level among study groups:                         52 
3.3.3 High density lipoprotein cholesterol (HDL) level among             
study groups                                                                                  
52 
3.3.4 Low density lipoproteins cholesterol (LDL) level among study 
groups:                                                                                      
53 
 
Chapter Four Discussion      
                
 
63 
4.1 The Survey                                                                                  64 
4.2 Thyroid status                                                                       64 
4.3 Serum lipids 65 
 
Conclusion                                                                      
 
 
69 
References                                                          
 
71 
 
 
 
 
 
 
 
 
 List of Tables 
 
Table  Page 
(1) Summary of the effects of thyroid hormones  8 
(2) Etiology of Hypothyroidism 11 
(3) The symptoms of hypothyroidism     12 
(4) The percentages of Sudanese subjects visited RIA Lab, SAEC 
during (1994-1996). 
35 
 
(5) The thyroid status among males and females under survey 36 
(6) The levels of thyroid and  thyroid related hormones 44 
(7) The results of triglycerides, total cholesterol, HDL- cholesterol  
  and LDL- cholesterol among the study groups. 
 
54  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 List of Figures 
 
Figure  Page 
(1) The type of visit to the RIA laboratory for the subjects under survey      37 
(2) The mean of age in years for patients under survey                       38 
(3) The prevalence of hypothyroidism (clinical and subclinical)  
compared to euthyroid among the Sudanese subjects (1994-1996) 
39 
(4) Mean of T4 in nmole/L for euthuroid and hypothyroid (clinical 
and subclinical) subjects under survey  
40 
(5) Mean of T3 in nmole/L for euthyroid and hypothyroid (clinical 
and subclinical) subjects under survey 
41 
(6) The mean of TSH in mIU/ml for euthyroid and hypothyroid 
(clinical and subclinical) subjects under survey 
42 
(7) Mean of age in years for euthyroid and hypothyroid (clinical and 
subclinical) subjects under study 
45 
(8) Mean values of T4 (nmole/L) among the Sudanese females 
(euthyroid and hypothyroid) under study 
46 
(9) Prevalence of T4 levels (nmole/L) among euthyroid and 
hypothyroid in the Sudanese Females  
47 
(10) Mean values of T3 (nmole/L) among euthyroid and hypothyroid 
Sudanese females under study 
48 
(11) Prevalence of T3 levels among euthyroid and hypothyroid 
Sudanese females under study 
49 
(12) Mean values of TSH (mIU/ml) among the euthyroid and 
hypothyroid Sudanese females under study 
50 
(13) The prevalence of TSH levels (mIU/ml)  among Sudanese 
females under study 
51 
(14) Mean values of TG (mg/dl) among the euthyroid and 
hypothyroid Sudanese females under study 
55 
(15) The prevalence of TG among euthyroid and hypothyroid 
Sudanese females under study 
56 
(16) Mean values of TC (mg/dl) among euthyroid and hypothyroid 
Sudanese females under study 
57 
(17) Prevalence of total cholesterol among euthyroid and hypothyroid 
Sudanese females under study 
58 
(18) Mean values of HDL-Cholesterol (mg/dl) among the euthyroid 
and hypothyroid Sudanese females under study 
59 
(19) The prevalence of HDL-cholesterol among euthyroid and 
hypothyroid of Sudanese females under study 
60 
(20) Mean values of LDL-cholesterol (mg/dl) among euthyroid and 
hypothyroid Sudanese females under study 
61 
(21) The prevalence of LDL-cholesterol among euthyroid and 
hypothyroid Sudanese females under study 
62 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
The endocrine glands and the nervous system constitute the control 
system in the body. They are responsible for monitoring animal's internal 
and external environments and making appropriate adaptive changes. The 
nervous system mediates its activity through nerves directly supplying the 
organs structures concerned, while the endocrine operates through 
chemical messengers known as hormones (Sukkar et al., 2000, Brook and 
Marshal, 2001). Endocrine hypo function can be due to destruction of the 
gland, extra glandular disorder or defects in hormone biosynthesis. The 
thyroid gland is the largest organ specialized for endocrine function in the 
human body (Greenspan and Gardner, 2004). The thyroid hormones 
maintain the level of metabolism in the tissues that is optimum for their 
normal function. They are well known to stimulate the oxygen 
consumption of most of the cell in the body, helps regulate lipid and 
carbohydrates metabolism, modulation of gonadotropin secretion by the 
pituitary and maintenance of proliferative cell growth and maturation in 
hair. In addition, thyroid hormones stimulate both sodium pump and 
glycolytic pathway leading to calorigenesis and oxidative 
phosphoralytion in tissues such as liver, kidney, and muscle (Ganog, 
2001). 
Hypothyroidism is a condition in which the thyroid gland does not 
make sufficient thyroid hormone to meet the body's requirements. In 
addition to the hypercholesterolemia and elevated low density 
lipoproteins (LDL) levels frequently observed in hypothyroidism, 
deficiency of thyroid hormones exert profound effects on triglycerides 
transport, often leading to hypertriglyceridemia. Availability of adequate 
thyroid hormone is essential for normal activity of lipoprotein lipase 
(LPL) (Williams, 1997).  
Radio Immuno Assay laboratory (RIA) of Sudan Atomic Energy 
Commission (SAEC) is the first laboratory that conducted the routine 
investigations of thyroid and thyroid-related hormones since 1985; most 
if not all of subjects were referred to this laboratory so it will be helpful 
to analyze the records of the thyroid and thyroid-related hormones to 
monitor the prevalence of different thyroid disorders among the Sudanese 
population whether males or females. The first part in this study is 
statistical survey for the records of thyroid and thyroid-related hormones 
from 1994 to 1996. These records were analyzed statistically using Excel 
Software of Microsoft. As most of the referred subjects to the endocrines 
laboratories are females the second part of this study was to evaluate the 
lipid profiles (total cholesterol, triglycerides, low -density lipoproteins- 
cholesterol, and high –density lipoproteins- cholesterol) in females with 
hypothyroidism (have low T4and high TSH) and sub clinical 
hypothyroidism (have normal T4 and T3 but have high TSH) (Hardman 
and Limbird, 2001) in comparison to euothyroid controls (have normal 
T4, T3 and TSH).  
Objectives 
1. To analyze results of hypo function of thyroid gland for subjects 
referred to RIA laboratory of SAEC (1994-1996) by using micro 
soft excel.   
2. To estimate the levels of lipid profiles from blood samples of 
Sudanese females that are either suffering from clinical or sub 
clinical hypothyroid function. 
3. To compare results obtained from objective 2 with results from 
euothyroid Sudanese females. 
4. To detect the effect of clinical and sub clinical thyroid 
hypofunction on the lipid metabolism. 
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CHAPTER ONE 
Literature Review 
 1.1 The thyroid gland     
 The adult human gland weight 10-20g, and is usually smaller in 
regions of the world in which supplies of dietary iodine are abundant. It is 
nearly always asymmetrical, with the right lope often twice the size of the 
left one. The thyroid usually larger in women than in men and it enlarge 
during puberty, during lactation and in the latter part of menstrual cycle. 
Seasonal changes have also been reported between summer and winter, 
decrease in thyroid mass frequently occurs in winter. The gland is 
enclosed by two connective-tissue capsules. The functional unit of the 
gland is the thyroid follicle or acinus. This consists of cuboidal epithelial 
(follicular) cells arranged as roughly spheroidal sacs, the lumen of which 
contains colloid. The latter is composed almost entirely of the iodinated 
glycoprotein called thyroglobulin (Brook and Marshal, 2001). The gland 
has a rich blood supply and the highest rate of blood flow per gram of 
tissue compared to any other organ. The amount is greatly increased 
when the gland is overactive. The sympathetic nerves supplying the gland 
have no direct effect on the secretary processes (Bell et al., 1972). 
1.1.2 Thyroid hormones: 
 Thyroid hormones are derivatives of the amino acid tyrosine bound 
covalently to iodine. The two principal thyroid hormones are : Thyroxine, 
which known affectionately as T4 or L-3, 5, 3', 5' tetraiodothyronine. 
Triiodotyronine that is known as T3 or L-3, 5, 3'-triiodothyronine. As 
shown in the following diagram, the thyroid hormones are basically two 
tyrosine residues linked together with the critical addition of iodine at 
three or four positions on the aromatic rings. The number and position of 
the iodine is important. Several other iodinated molecules are generated 
that have little or no biological activity; so called "reverse T3" (3, 3', 5'-
T3) is such an example.  
 
 
     A large majority of the thyroid hormone secreted from the thyroid 
gland is T4, but T3 is the considerably more active hormone. Although 
some T3 is also secreted, the bulk of the T3 is derived by deiodination of 
T4 in peripheral tissues, especially liver and kidney. Deiodination of T4 
also yields reverse T3, a molecule with no known metabolic activity. T3 
and T4 are synthesized in the colloid by iodination and condensation of 
tyrosine molecules bound in peptide linkage in thyroglobulin 
(glycoprotein contains 10% carbohydrate and 123 tyrosine residues). 
Thyroglobulin is synthesized in the thyroid gland cells and secreted into 
the colloid by exocytosis of granules that also contain thyroid peroxidase. 
The thyroid cells thus have three functions: they collect and transport 
iodine; they synthesize thyroglobulin and secrete it into the colloid and 
they remove the thyroid hormones from thyroglbulin and secrete them 
into the circulation. Thyroid hormones are poorly soluble in water, and 
more than 99% of the T3 and T4circulating in blood are bound to carrier 
proteins. The principle carrier of thyroid hormones is thyroxine-binding 
globulin, a glycoprotein synthesized in the liver. Two other carriers of 
import are transthyrein and albumin. Carrier proteins allow maintenance 
of a stable pool of thyroid hormones from which the active, free 
hormones are released for uptake by target cells. (Ganong, 2001).  
1.1.3 Relation of Iodine to thyroid function  
      Iodine forms an integral part of the thyroxine and tri-iodothyronine 
molecules. Iodine is taken in food and in drinking water. A minimum 
daily intake of about 100_150 µg (in the form of potassium or sodium 
iodide) is required for normal thyroid function. The iodide is easily 
absorbed in the intestine to circulate in the plasma in a concentration of 
about 0.3 µg /100 ml; 30_50% of iodide circulating in the blood is taken 
up by the thyroid, while the rest is lost in the urine. The thyroid can 
therefore remove iodide from the blood against a concentration gradient 
ranging from about 40 times in a normal gland to several hundred times 
in an over active gland. This selective uptake of iodide by the thyroid 
gland, or iodide trapping, can be achieved only by active transport (iodide 
pump). The trapped iodide ions are oxidized into iodine in thyroid cell by 
means of peroxidase enzyme. The oxidized form is capable of combining 
with tyrosine (Sukkar et al., 2000). 
Adult hypothyroidism and cretinism may occur in more severe iodine 
deficiency. In some areas of the world, simple or non toxic goiter is 
prevalent because dietary iodine is not sufficient (Hardman and Limbird, 
2001). 
 
 
1.1.4 Thyroid hormones action 
 Although the thyroid gland produces more T4 than T3, the latter 
hormone is more potent and acts much faster than the former. T3 enters 
the cell more easily than the T4. The latter is also transformed to T3 in the 
cytoplasm. T3 binds avidly to receptors on the cell nucleus and promotes 
messenger ribonucleic acid (m RNA) and ribosomal RNA (rRNA) 
synthesis. In most of its actions, T3 acts more rapidly and is three to five 
times more potent than T4. This is because it is less tightly bound to 
plasma proteins but binds more avidly to thyroid hormone receptors. RT3 
is inert. The nuclear receptors for thyroid hormones are considered as 
nuclear transcription factors. One such receptor (TRß2) is found in the 
brain cells only. Other receptors are found in almost all other body tissues 
(Sukkar et al., 2000). It is likely that all cells in the body are targets for 
thyroid hormones. While not strictly necessary for life, thyroid hormones 
have profound effects on many "big time" physiologic processes, such as 
development, growth and metabolism. Some of the widespread effects of 
thyroid hormones in the body are secondary to stimulation of O2 
consumption (calorigenic action), although the hormones also affect and 
regulate lipid metabolism, and increase the absorption of carbohydrates 
from the intestine (Hardman and Limbird, 2001). Thyroid hormones 
increase the dissociation of oxygen from hemoglobin by increasing red 
cell 2, 3-diphosphoglycerate (DPG). The variety of receptors and 
therefore transcription of a variety of enzymes explains the wide range of 
effect of thyroid hormones which are shown in table 1 (Sukkar et al., 
2000). 
 
 
 
 
Table(1): Summary of the effects of thyroid hormones (Sukkar et al, 2000). 
On metabolism 
Increase metabolic rate 
Increased O2 consumption  
Calorigenic effect 
Increased Na+, KATPase  activity 
Fat mobilization 
Increased absorption of glucose in the small intestine  
Increased formation of LDL receptors 
Growth and development 
Normal skeletal growth 
Mental development 
Central nervous system  
Brain development 
Potentiation of catecholamines, enhanced alertness 
Decreased reflex time  
Cardiovascular system 
Increased contractility of cardiac muscles and increased heart rate 
Potentiation of catecholamines through increased numbers and 
affinity of B-adrenergic receptors  
On reproduction 
Normal gonadal function 
Milk production 
On bone marrow 
Normal erythropoesis 
 
1.1.5 Control of thyroid function 
      The activity of thyroid gland is controlled by thyroid –stimulating 
hormone (TSH) from the anterior pituitary gland: the secretion of this is 
controlled by thyrotrophin releasing hormone (TRH) from the 
hypothalamus. Thyroid hormones (T4 and T3) suppress (TSH) secretion 
negative feedback (Brook and Marshal, 2001). TSH influences the 
thyroid functions in different ways. It increases the vascularity of the 
gland to facilitate more efficient removal of the hormones from the gland. 
TSH stimulates the steps involved in the synthesis and release of thyroid 
hormones, from the process of iodide trapping to the activation of 
proteases which liberate thyroid hormones from their attachment to the 
thyroglobulin molecule into the colloid (Sukkar et al., 2000). 
 
1.1.6 Abnormalities in thyroid function 
       All thyroid disturbances are more common in females than in males 
(Sukkar et al., 2000). Disorders of the thyroid are common. They consist 
of two general presentations: changes in the size or shape of the gland or 
changes in secretion of hormones from the gland (Hardman and Limbird, 
2001). Goiter refers to any enlargement of thyroid gland, with or without 
disturbance of thyroid function (Sukkar et al., 2000). Hypothyroidism is a 
clinical syndrome resulting from adeficiency thyroid hormones, which in 
turn results in a generalized slowing down of metabolic processes 
(Greenspan and Gardner, 2004). Sub clinical hypothyroidism is an 
asymptomatic state characterized by elevated serum TSH concentration 
while serum T4 and T3 concentrations remain within the normal range 
(Hardman and Limbird, 2001). When the deficiency is congenital is 
referred to as cretinism. When deficiency of thyroid hormone is not 
congenital, the condition is referred to as myxoedema. Hyperthyroidism, 
which is characterized by high blood levels of thyroid hormones, can 
occur at an early age or it may occur later in life (Sukkar et al, 2000). The 
term sub clinical hyperthyroidism is defined as few if any symptoms with 
a low serum TSH and normal concentrations of T4 and T3 (Hardman and 
Limbird, 2001).   
1.2.1 Hypothyroidism 
Hypothyroidism is a condition in which the thyroid gland does not 
make sufficient thyroid hormone to meet the body's requirements. 
Hypothyroidism is often referred to as an "under active thyroid gland". 
Caused in almost all cases by autoimmune disease, the result is that the 
immune system goes awry and begins gradually to destroy the thyroid 
gland. This process is not usually associated with thyroid gland 
discomfort but may cause the gland to enlarge or shrink in size. 
Another important cause of hypothyroidism is the treatment of 
hyperthyroidism (an overactive thyroid gland), which often causes the 
thyroid gland to fail after a numbers of years. (Brook and  Marshal, 
2001). 
1.2.2 Etiology and incidence of hypothyroidism 
 Hypothyroidism can be classified as (1) primary (thyroid failure), 
(2) secondary (to pituitary TSH deficit), or (3) tertiary (due to 
hypothalamic deficiency of TRH) or may be due to (4) peripheral 
resistance to the action of thyroid hormones, (Table 2). The incidence of 
various causes of hypothyroidism will vary depending on geographic and 
environmental factors such as dietary iodine and goitrogen intake, the 
genetic character,  and the age distribution of the population (pediatric or 
adult) (Greenspan and Gardner,  2004). 
Table (2): Etiology of Hypothyroidism: (Greenspan and Gardner, 
2004). 
 
 
 
 
 
Primary: 
1. Hashimoto's thyroiditis: 
a. With goiter. 
b. "Idiopathic" thyroid atrophy, presumably end- stage autoimmune 
thyroid disease, following either Hashimoto's thyroiditis or 
Grave's disease. 
c. Neonatal hypothyroidism due to placental transmission of TSH- R 
blocking antibodies. 
2. radioactive  iodine therapy for Grave's disease 
3. Subtotal thyroidectomy for Grave's disease or nodular goiter. 
4. Excessive iodine intake (Kelp, radio contrast dyes). 
5. Sub acute thyroiditis. 
6. Iodine deficiency. 
 
Secondary: 
Hypopiuitrism due to pituitary adenoma, pituitary ablative therapy, or 
pituitary destruction. 
 
Tertiary: 
Hypothalamic dysfunction (rare) 
 
Peripheral resistance to the action of thyroid hormone. 
1.2.3 Symptoms of hypothyroidism  
The clinical signs and symptoms of hypothyroidism which are 
show in table 3 are manifest when the disease is fully developed. 
But even in the earliest (sub clinical stage), one or more of these 
findings may occur (Hardman and Limbird, 2001). 
 
Table(3): The symptoms of hypothyroidism (Hardman and Limbird, 2001).               
Signs and Symptoms of Hypothyroidism 
Weakness, lethargy, fatigue:  
Dry skin 
Coarse hair 
Cold intolerance  
Constipation 
Weight gain  
Muscle cramps  
Edema of eyelids, face, legs (nonpitting)  
Hoarseness  
Hearing loss  
Menorrhagia  
Slowing of return phase of reflexes (e.g., knee jerk)  
Bradycardia 
 
 
1.3 Sub clinical Hypothyroidism 
Sub clinical hypothyroidism is defined as an asymptomatic state 
characterized by normal serum concentration of free thyroxine and 
elevated serum concentration of thyroid stimulating hormone (TSH) 
(Helfand and Rdfern, 1998). This biochemical state has been given a 
variety of other names, including mild thyroid failure, as well as 
compensated, early, late, mild, minimally symptomatic, and pre-clinical 
hypothyroidism (Arem and Escalante, 1996). 
1.3.1 Causes 
Subclinical hypothyroidism is caused by the same disorders of the 
thyroid gland as those that cause overt hypothyroidism such as chronic 
autoimmune thyroiditis, treated Graves' disease, congenital, 
hypopituitarism, iodine deficiency, radioactive therapy & antithyroid 
drugs. Chief among these is chronic autoimmune thyroiditis (Hashimoto's 
disease), which is commonly associated with increased titers of 
antithyroid antibodies. (Adlen, 1998). Medications such as lithium and 
aminodarone, sulfonyl ureas and ethioamide can interfere with thyroid 
hormone production or release and secondary result in a slight elevation 
of (TSH) (Kek et al., 2003). 
1.3.2 Clinical Implications 
Clinical manifestations of subclinical hypothyroidism include 
abnormal lipid metabolism, cardiac dysfunction, and several cross-
sectional studies have suggested that it confers an elevated risk of 
atherosclerosis and coronary heart disease. However, neither of these 
associations has been confirmed by others (Imaizumi et al., 2004). 
 
 
 
1.4 The Plasma lipids 
Because lipids are relatively insoluble in water, they are 
transported in association with proteins. The simplest complexes are 
those formed between unesterified, or free, fatty acids (FFA) and 
albumin, which serve to carry the FFA from peripheral adipocytes to 
other tissues. The remainders of lipids are transported in spherical 
lipoprotein complexes, with core regions containing hydrophobic lipids. 
The principal core lipids are cholesterol esters and triglycerides 
(Greenspan and Gardner, 2004). The proteins known as apolipoprotein or 
apoprotein .The apoprotein are very important since they provide 
structural stability to the lipoproteins, and a number of apoproteins 
function as ligands in lipoprotein-receptor interactions or as cofactors in 
enzymatic processes that regulate lipoprotein metabolism (Hardman and 
Limbird, 2001). In addition to FFA, four major groups of lipoproteins 
have been identified that are important physiologically and in clinical 
diagnosis. These are (1) chylomicrons; derived from intestinal absorption 
of triacylglycerol; (2) very low density lipoproteins (VLDL), derived 
from the liver for the export of triacyglycerol; (3) low density 
lipoproteins (LDL), representing a final stage in the catabolism of VLDL 
;and (4) high density lipoproteins (HDL), involved in VLDL and 
chylomicron metabolism and also in cholesterol transport. Triacylglycerol 
is predominant lipids in chylomicrons and VLDL, whereas cholesterol 
and phospholipids are the predominant lipids in LDL and HDL, 
respectively. Abnormalities of lipoproteins metabolism occur at the sites 
of production or utilization of lipoproteins, causing various hypo- or 
hyperlipoproteinemias (Murray et al., 2000). 
 
 
 
1.4.1 Cholesterol metabolism    
Cholesterol is the precursor of the steroid hormones and bile acids 
and is an essential constituent of cell membranes. It is found only in 
animals. Related sterols occur in plants, but plant sterols are not normally 
absorbed from the gastrointestinal tract. Most of dietary cholesterol is 
contained in egg yolks and animal fat. Cholesterol is absorbed from the 
intestine and incorporated into the chylomicrons formed in the mucosa. 
After chylomicrons discharge their triglyceride in adipose tissues, the 
chylomicrons remnants bring cholesterol to the liver. The liver and other 
tissues also synthesize cholesterol. Some of the cholesterol in the liver is 
excreted in the bile, both in the free form and as bile acids. Most of the 
cholesterol in the liver is incorporated into VLDL, and all of it circulates 
in lipoprotein complexes (Ganong, 2001).  Cholesterol is synthesized 
from acetyl-CoA via a complex pathway. Three molecules acetyl-CoA 
form mevalonate via the important rate-limiting reaction for pathway; 
catalyzed by 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase 
(Murray et al., 2000). Thus, when dietary cholesterol intake is high, 
hepatic cholesterol synthesis is decreased, and vise versa. The plasma 
cholesterol level is decreased by thyroid hormones, which increase the 
number of LDL receptors in the liver (Ganong, 2001).  
 
1.4.2 Low Density Lipoproteins  
LDL is the primary plasma carriers of cholesterol for delivery to all 
tissues. The exclusive apolipoprotein of LDL is apoB-100. LDL is taken 
up by cells via LDL receptor-mediated endocytosis. A small component 
is mediated by nonreceptor clearance mechanisms (Brown and Goldstein, 
1986). The uptake of 75%LDL occurs predominantly in the liver 
(Dietschy et al., 1993). 
 
The interaction of LDL with LDL receptors requires the presence of 
apoB-100. The endocytosed membrane vesicles (endosomes) fuse with 
lysosomes, in which the apoproteins are degraded and the cholesterol 
esters are hydrolyzed to yield free cholesterol. The cholesterol is then 
incorporated into the plasma membranes as necessary. Excess 
intracellular cholesterol is re-esterified by acyl-CoA-cholesterol 
acyltransferase (ACAT); for intracellular storage. The activity of (ACAT) 
is enhanced by the presence of intracellular cholesterol. Thyroxine and 
estrogen enhance LDL receptor gene expression, which explains the 
LDL-C lowering effects of these hormones (Windlerr et al, 1980 and 
Wiseman et al., 1993). The elevated LDL cholesterol levels in 
hypothyroidism may occur as a result of increased cholesterol synthesis 
and absorption (Abrams et al., 1981) decreased hepatic lipase and 
lipoprotein lipase activities (Valdemarsson and Nilsson-Ehle, 1982), and 
defects in the receptor-mediated catabolism of LDL (Chait et al., 1979 
and Thompson et al., 1981). The elevation in LDL levels, in turn, may be 
accompanied by increased formation of oxidized LDL, which may 
contribute to the enhanced risk for atherosclerosis in these individuals 
(Oge et al., 2004). 
 
1.4.3 High Density Lipoproteins, (HDL) 
The metabolism of HDL is complex because of the multiple 
mechanisms by which  HDL particles are modified in the plasma 
compartment and by which HDL particles are synthesized (Tall et al.,  
2000). ApoA-1 synthesis is required for normal production of HDL. 
Mutations in the apoA-1 gene that cause HDL deficiency are variable in 
their clinical expression and often associated with accelerated 
atherogenesis (Hardman and Limbird ,2001).Conversely, over expression 
of apoA-1 in transgenic mice protects against experimentally induced 
atherogenesis (Pulump et al.,  1994).   
 
      The precursor of the most of the plasma HDL is a discoidal particle 
containing apoA-1 and phospholipid, called pre-ß1 HDL because of its 
pre- ß1 electrophoreic mobility. Pre-ß1 HDL are synthesized by the liver 
and the intestine, and they also arise when surface phospholipid and apo 
A-1 of chylomicrons and VLDL are lost as the triglycerides of these 
lipoproteins are hydrolyzed. Phospholipid transfer protein plays an 
important role in the transfer of phospholipids to the HDL (Tall et al., 
2000). After free cholesterol is acquired by the pre- ß1 HDL, it is 
esterified by lecithin: cholesterol acyltransferase (LCAT).    
    
Cholesterol-rich HDL return to the liver, where they are 
endocytosed. Hepatic uptake of HDL, or reverse cholesterol transport, 
may be mediated through an HDL-specific apoA-I receptor or through 
lipid-lipid interactions. HDL also acquires cholesterol by extracting it 
from cell surface membranes. This process has the effect of lowering the 
level of intracellular cholesterol, since the cholesterol stored within cells 
as cholesteryl esters will be mobilized to replace the cholesterol removed 
from the plasma membrane. 
 
 The cholesterol esters of HDL can also be transferred to VLDL and 
LDL through the action of the HDL-associated enzyme, cholesterol ester 
transfer protein (CETP). This has the added effect of allowing the excess 
cellular cholesterol to be returned to the liver through the LDL-receptor 
pathway as well as the HDL. HDL is protective lipoproteins that decrease 
the risk of coronary heart disease (CHD); thus, high levels of HDL are 
desirable. This protective effect may result from participation of HDL in 
reverse cholesterol transport, the process by which excess cholesterol is 
acquired from cells and transferred to the liver for excretion. HDL also 
may inhibit oxidative modification of LDL through the action of 
paraxonase, an HDL-associated antioxidant protein (Hardman and 
Limbird, 2001). Thyroid hormones appear to stimulate virtually all 
aspects of lipid metabolism, including synthesis mobilization, and 
degradation (Williams, 1997). 
 
1.5 Hyperlipidemia and Hypothyroidism 
 In addition to the hypercholesterolemia and elevated LDL levels 
frequently observed in hypothyroidism, deficiency of thyroid hormones 
exert profound effects on triglycerides transport, often leading to 
hypertriglyceridemia. Availability of adequate thyroid hormone is 
essential for normal activity of LPL. In hypothyroidism, low LPL activity 
appears to be reciprocally related to hypertriglyceridemia, and the 
abnormalities.The relationship between mild thyroid failure and 
reversible elevation in serum lipid levels has been widely investigated, 
but, the findings remain controversial. In patients with full-blown 
hypothyroidism, serum levels of triglycerides (TG), total cholesterol and 
low-density lipoproteins (LDL) cholesterol are elevated. In patients with 
sub clinical hypothyroidism, not surprisingly, the same changes are 
present but are less marked and less consistent. This pattern of lipid 
abnormalities, of course, is important because it is a risk factor for 
atherosclerotic cardiovascular disease (Adlen, 1998). Hypothyroidism can 
alter lipoprotein metabolism in the following ways: decrease lipoprotein 
lipase activity, increase hepatic production of LDL-C, decrease LDL-C 
receptor activity, and reduce HDL-C binding to hepatocytes. It has been 
suggested that patients with hypothyroidism are at increased risk for 
coronary artery disease. Atherogenic changes in the lipid profile, such as 
elevation of levels of TC, LDL-C, and TGs, have been described. 
Changes in HDL-C, apolipoprotein (apo) A-I, and lipoprotein (a) (LP[a]) 
have been noted to vary (Diekman et al., 1995). 
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2.1. The Survey 
       A general survey was carried out for the records of thyroid function 
test to subjects visited the SAEC laboratories during 1994-1996. The 
study focused on the variation in sex, age and subject's status, whether 
they were new cases or under treatment this is related to their thyroid 
status. The statistical analysis was done using statistical package for 
social science (spss) and excel software of Microsoft.  
2.2. Subjects 
    One hundred and twenty adult female patients their ages ranging 
between 30-55 years were selected from the subjects referred to the 
Radiation and Isotopes Center, Khartoum (RICK), Radio- immunoassay 
laboratory, during February, 2005 to July, 2005, suspected as cases of 
thyroid dysfunction. Subjects were divided into three equal groups: 
euthyroid as control, hypothyroidism and subclinical hypothyroid group. 
Subclinical hypothyroidism is a condition in when there is small elevation 
in thyroid stimulating hormone, yet normal circulating levels of thyroid 
hormones (William and William, 2004) .In the present study subjects that 
considered as sub clinical hypothyroid cases had serum TSH levels 
between (6.0-10 mIU/l) and euthyroid values for T3 and T4. 
 
2.3. Samples and sampling techniques 
Blood samples (5 ml) were collected from cubital vein after 
overnight fasting. The blood samples were allowed to clot at room 
temperature and then centrifuged at 4000 R.P.M to obtain the serum. The 
clear serum was taken immediately for analysis or stored at -20 C ْ for 
further use. 
 
2.4. Laboratory methods 
The levels of TSH, T4, and T3 were estimated by using 
Radioimmunoassay (RIA) techniques, while commercial enzymatic 
methods were used for determination of total cholesterol, triglycerides, 
LDL-cholesterol, and HDL-cholesterol.  
 
2.4.1. Radioimmunoassay (RIA) 
(RIA) kits are all supplied by the Department of Isotopes, China 
Institute of Atomic Energy, 1994. Each Kit has specific code: IMK-437, 
IMK-438, and IMK-432 for T4, T3 and TSH respectively. 
 
2.4.1.1. T4 kits 
These kits consisted of 6 vials of lyophilized standards T4 to give 
different concentrations when reconstituted by 1 ml of distilled water; 
(0.0, 26, 52, 103, 206 and 309 nmole/l) thyroxin.  
One vial of T4-I125 tracer and T4 antibodies coupled to magnetic 
particles, and one vial for quality control (QC) sample. 
 
2.4.1.2. T3 kit 
Includes 6 vial of triiodothyronine standard solution in different 
concentrations, (0.0, 0.5, 1.0, 2.0, 4.0 and 8.0 nmol/l).       
One vial contains T3-I125 tracer, one vial Anti-T3 antibody, and one vial 
of (QC) sample. 
 
2.4.1.3. Thyroid stimulating hormone (TSH) kit 
Contains 7 vials of standard solutions of TSH; their concentrations as 
follow: A. 0.0, B. 0.23, C. 1.0, D. 3.0, E. 10.0, F.20.0 and G. 80.0 mIU/L. 
 One vial contain anti-TSH antibodies coupled to magnetic particles, 
(solid phase separation system), one vial of tracer (labeled anti TSH with 
I125, one vial wash Buffer, 3 vial of QC samples A, B and C with different 
ranges. 
Equipment 
1. Adjustable micropipettes (10-200µl) with disposable tips. 
2. Polystyrene test tubes (disposable). 
3. Vortex mixer (single and multi-tubes). 
4. Multidose micropipette. (Eppendorfe).25µl and 250 µl, magnetic 
base (separator). 
5. Water bath. 
6. Incubator. 
7. Centrifuge. 
8. Gamma counter, connected with computer contains (IAEA) 
programme (International Atomic Energy Agency). 
2.4.1.4. T4 assay procedure 
Sufficient (polystyrene) test tubes were labeled in duplicates and 
arranged in assay rack, and then 25 µl were pipetted into each tube of the 
standards, quality control sample and patient's sample. And 250 µl anti 
T4 antibody were added to each tube, and mixed well, to the STD and QC 
and samples 250 µl of tracer were added. 
After good mixing tubes were incubated at 37o C in the incubator 
for 45 minutes, then the rack was placed in the magnetic base for 10 
minutes, to separate the bound fraction from the free fractions by 
decanting the supernatant.  Lastly each tube was counted in the gamma 
counter to evaluate the gamma emission per minutes, and binding percent 
was plotted vs. the concentration, to get standard calibration curve, and 
from the obtained curve the concentration of thyroxin in the patient's 
samples was evaluated. This method is bioassay method, 
(Radioimmunoassay), Using radio active isotope of iodine (I125) which is 
gamma emitter.  
2.4.1.5. T3 assay 
Sufficient number of test tubes were labeled in duplicate and 
arranged in assay rack. 25 µl of standard solutions, QC samples and 
patients sample were added to each target tube. 250 µl of T3- I125 tracer 
and 100 µl anti-T3 antibodies were added to each tube and mixed, the 
tubes were incubated at 37oC for one hour and then vortex well and 
centrifuged to separate bound fraction, (liquid phase separation system). 
The supernatant was decanted and then each tube was placed in gamma 
counter. The principle of the assay is the same as that for T4. 
2.4.1.6. TSH assay 
Sufficient test tubes were labeled and arranged in assay rack in 
duplicates. 100 µl of STD and QC and samples were pipetted in target 
tubes and 25 µl tracer (anti TSH labeled by I125) were added to each tube 
and vortexed gently, and then incubated at 37Co in the incubator for one 
hour. 250 µl of anti TSH (antibody coupled to magnetic particles) were 
added to each tube and well mixed and incubated at 25oC for one hour. 
Then the racks were placed in the magnetic separator for 10 minutes and 
the supernatant was separated by decantation.    
 
 Wash Step 
In this step, first the concentrated wash buffer was diluted by 
adding water (1:9), and then 500 µl of the diluent was added to each tube 
and then vortexed well and then placed again in the magnetic base and 
allowed to stand for 10 minutes. Then the supernatant was decanted and 
drained thoroughly on adsorbent paper. The wash step was repeated 
again. All the tubes were counted in the gamma counter, to evaluate the 
concentration of TSH in the patient sample. 
The quantitative analysis of TSH is achieved by the above method, 
which is immunoradiometric method. It is non- competitive method in 
which the radio active compound (tracer) is TSH antibody. There are two 
antibodies react with the TSH in the analyte to get a sandwich complex. 
Calculation of results 
The results in these two methods are obtained by using 
computerized method in which software provided from International 
Atomic Energy Agency (IAEA) was used. 
     The count per minute of each tube was counted in the Gamma counter, 
to get the emission from all tubes in one minute including the patients 
samples, the standard curve was plotted, the concentration of T3, T4, TSH 
standards in the X axis Vs. the bound percentage (the count of each 
standard over the total count B/T%) in the y axis. 
  
          
 
Then concentration of each sample was calculated from the standard 
curve (normal interpolation). 
 
2.4.2. Estimation of Serum Lipids 
Equipments and reagents 
1. Polystyrene test tubes (disposable). 
2. Vortex mixer (single and multi-tubes). 
3. Multidose micropipette. (Eppendorfe).25µl and 250 µl, 
4. Water bath. 
5. Spectrophotometer (Biosystem 305- BTS), with 500 nm filter (490-510). 
Count of std/sample 
Total count 
Binding%=                                        ×100 
• All kits and reagents were supplied by Biosystem Company, for 
reagents and instruments. Methods and procedures are applied according 
to the instruction described in the kits manuals. Each Kit has specific 
code: 11505 (1 X 200 ml), 11648, 11579, and 11528 for Cholesterol, 
HDL-C, LDL-C, and TG respectively. 
2.4.2.1. Estimation of total cholesterol 
Principle of the method 
 In the presence of cholesterol esterase, the cholesterol esters in the 
sample are hydrolyzed to cholesterol and free fatty acids. The cholesterol 
produced is oxidized by Cholesterol oxidase to cholestenone and hydrogen 
peroxide. Hydrogen peroxide is detected by a chromogenic oxygen acceptor, 
phenol- ampyrone, in the presence of Peroxidase. The red quinine formed is 
proportional to the amount of cholesterol present in the sample. (Deeg and 
Ziegenhorn 1983). 
Cholesterol ester + H2O                     CHE          Cholesterol + fatty acid 
Cholesterol + 1/2 O2 +H2                   CHOD        Cholesterol + H2O2 
2H2O2 + Aminoantipyrine + Phenol      POD         Quinoniemine +4H2O 
 
Contents and composition of reagents 
1- Reagent-1 (Buffer):  PIPES PH 6.9 90 mmol/l, phonol 26 mmol/l 
2- Reagent-2 (Enzymes): Cholesterol esterase (CHE) 300 U/ml, 
Cholesterol oxidase (CHOD) 300 U/L, Peroxidase (POD) 1250 U/ml,   
4-aminoantipyrine (4-AP) 0.4 mmol/l, pH 7.0. 
3- Cholesterol standard 200 mg/dl. 
Procedure 
1- The working reagent was prepared by dissolving one vial of Reagent-
2 enzymes in one bottle of reagent-1 Buffer.   
2- The working reagent was brought to room temperature. 
3- Into labeled test tubes the following were pipetted: 
 Blank (B) Standard (STD) Sample (S) 
Cholesterol standard  10 µl   
Sample - - 10 µl 
Working reagent 1.0ml 1.0ml 1.0ml 
4- The tubes were incubated for 10 minutes at room temperature (16-25 C)ْ. 
5- The absorbance (A) of the standard and the samples were measured at 
500 nm against the blank. 
Calculatoins 
Cholesterol (mg/dl) =  AS  X 200 
          AST  
AS: means absorbance of the sample.       AST: means absorbance of the 
standard   
2.4.2.2. Estimation of high- density lipoprotein Cholesterol(HDL-C) 
Principle of the method 
 Very low-density lipoprotein (VLDL) and low density lipoprotein 
(LDL) in the sample are precipitated with phosphotungsate and magnesium 
ions. The supernatant contains high-density lipoproteins (HDL). The HDL-
cholesterol is then spectrophotometerically measured by means of the 
coupled reactions as described in total cholesterol previously. 
Contents and composition of reagents 
1- Reagent B: 50 ml, phosphotungsate 0.4 mmol/L, magnesium chloride 
20 m mol/L 
2- HDL-cholesterol standard 3 ml cholesterol 40 mg/dL 
3- Cholesterol Kit (Biosystmcode. 11505, 11506, 11539) 
Procedure 
Precipitation 
1- Into labeled test tubes the following were pipetted: 
Sample 0.2 ml 
Reagent B 0.5 ml 
2- The tubes were let to stand for 10 minutes at room temperature. 
3- Centrifuged at minimum of 4000 r.p.m for 10 minutes. 
4- The supernatant was collected carefully. 
Colorimetry  
1- The cholesterol reagent was brought to room temperature. 
2- Into labeled test tubes the following were pipetted: 
 Blank (B) Standard (STD) Sample (S) 
Distilled water 20 µl - - 
Cholesterol 
standard 
 20 µl - 
Sample supernatan - - 20 µl 
Cholesterol reagen 1.0 ml 1.0 ml. 1.0 ml 
3- The tubes were incubated for 10 minutes at 37 C.ْ 
4- The absorbance (A) of the sample and the standard were measured at 
500 nm against the blank. 
Calculations 
HDL-cholesterol (mg/dl) = AS   X 3.5 X 40      
            ASt 
2.4.2.3. Estimation of low- density lipoprotein cholesterol (LDL-C) 
Principle of the method 
 Low- density lipoprotein (LDL) in the sample is precipitated with ploy 
vinyl sulphate. Their concentration is calculated from the difference between 
the serum total cholesterol in the supernatant after centrifugation. The 
cholesterol is spectrophotometerically measured by means of the coupled 
reactions as described in total cholesterol previously. 
Contents and composition of reagents 
1- Reagent B: 10 ml polyvinyl sulphate 3 g/L, polyethylene glycol 3 g/L. 
2- Cholesterol kit (Biosystem code 11505, 11506, 11539). 
 
Procedure 
Precipitation 
1- Into labeled test tubes the following were pipetted: 
Sample 0.2 ml 
Reagent B 0.1 ml 
2- The tubes were let to stand for 10 minutes at room temperature. 
3- Centrifuged at minimum of 4000 r.p.m for 10 minutes. 
4- The supernatant was collected carefully. 
Colorimetry  
1- The cholesterol reagent was brought to room temperature. 
2- Into labeled test tubes the following were pipetted: 
 
 
 
 
 
 
 
 
 
 Blank (B) Standard (STD) Sample (S) 
Distilled water 20 µl -  - 
Cholesterol standard - 20 µl - 
Sample supernatant - - 20 µl 
Cholesterol reagent 1.0 ml 1.0 ml. 1.0 ml 
3- The tubes were mixed and incubated at room temperature for 30 minutes. 
4- The absorbance (A) of the sample and the standard were measured at 500 
nm against the blank. 
Calculations 
 The dilution factor of the sample in the precipitation is 1.5 and the 
concentration of the standard is 200 mg/dL according to the following 
formula is; 
cholesterol in the supernatant (mg/dl) =  As  X 1.5 X 200      
    Ast 
LDL- cholesterol = Total- cholesterol     Cholesterol in the supernatant. 
2.4.2.4. Estimation of triglycerides 
Principle of the method 
Triglycerides in the sample originate, by means of the coupled 
reactions described below, a colored complex that can be measured by 
spectrophotometry (Fossati and Prencipe, 1982). 
Triglycerides + H2O            lipase                 Glycerol + Fatty acids 
Glycerol + 3ATP       glycerol kinase            Glycerol-3-p + 3ADP   
Glycrtol-3-p + O2       G3p-oxidase        Dihydroxyacetone-p + H2O2  
2H2O2 + 4-Aminoantipyrine + 4-cholesterol peroxidase Quinoneimine + 4H2O 
 
Contents and composition of reagents 
 
1- Reagent A.  PIPES 45mmol/L, magnesium chloride 5mmol/L, 4-
chlorophenol 6mmol/L, lipase > 100 U/ml, glycerol kinase > 1.5 
U/ml, glycerol-3-phosphate oxidase > 4 U/ml, peroxidase > 0.8 
U/ml, 4-aminoantipyrine 0.75mmol/L, ATP 0.9mmol/L, PH 7.5. 
2- Triglycerides standard. Glycerol equivalent to 200 mg/dl triolein. 
 
Procedure 
1- The Reagent was brought to room temperature. 
2- Into labeled test tubes the following were pipetted: 
 
   Blank (B) Standard 
(STD) 
Sample (S) 
Triglycerides standard - 10µL - 
Sample - - 10µL 
Reagent 1.0mL 1.0mL 1.0mL 
3- The tubes were incubated for 15 minutes at room temperature. 
4- The absorbance (A) of the standard and sample was measured         
 at 500 nm against the blank. 
Calculations  
triglycerides (mg/dL) = AS  X  200    
   ASt 
2.5. Statistical analysis 
Statistical analysis was done using the Statistical Package for Social 
Sciences (SPSS 10.1). Different statistical methods were used as 
appropriate. Mean + SD was determined for quantitative data and 
frequency for categorical variables. 
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Chapter Three 
Results 
 3.1 The survey  
3.1.1Statistical analysis of subjects who referred to the RIA 
laboratory, of SAEC (1994-1996):  
      The Sudanese subjects who referred to the RIA laboratory of SAEC 
to do thyroid function test during the period from1994 to  1996 were 
about 4268  ; among them 3730 females that represent 87.4% compared 
to 538 males represent 12.6%. 85.13% of them were new cases and 
14.87% were under treatment .The percentage of hypothyroidism, 
subclinical hypothyroidism and euothyroid among male subjects were 
about 1.6, 6.1 and 75.80% respectively.  
 
         New cases females were about 85.42%, while 14.58% under 
treatment. Whereas, the percentage of hypothyroidism, subclinical 
hypothyroidism and euothyroid among female subjects were about 4.6, 
6.2 and 78.3% respectively (table 5). However, almost 85% of the 
referred patients visited the RIA laboratory for the first time as shown in 
table (4). 
 
  Table (4) The percentages of Sudanese subjects visited RIA Lab, 
SAEC during (1994-1996). 
Under treatment New cases Sex 
no % no % 
total 
Male 80 14.87 458 85.13 538 
Female 544 14.58 3186 85.42 3730 
Total 624 14.71 3644 85.29 4268 
 
          
   Fig (1) shows the type of visit to the RIA laboratory for the group under 
survey while fig (3) shows the results of thyroid function test for both 
males and females; who visited the RIA laboratory at SAEC during the 
period 1994 to 1996. However, fig (4), (5) and (6) represent the mean 
values for T4, T3 and TSH for Sudanese subjects respectively. 
 
Table (5) The thyroid status among males and females under survey 
 
Category  Prevalence among 
Sudanese males (%) 
Prevalence among 
Sudanese females (%) 
Euthyroid 67.1% 71.4% 
Hypothyroid  1.7% 4.7% 
Subclinical 
hypothyroid 
6.13% 
 
6.2% 
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Fig (1): The type of visit to the RIA laboratory for the subjects under 
survey. 
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Fig (2):  Mean of age in years for patients under survey. 
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Fig (3): The prevalence of hypothyroidism (clinical and subclinical) 
compared to euothyroid among the Sudanese subjects (1994-1996). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
020
40
60
80
100
120
Mean of 
T4
Males Females
Hypothyroid
Subclinical
hypothyroid
Euthyroid
 
 
 
 
 
Fig (4): Mean values of T4 (nmole/L) for euothyroid and hypothyroid 
(clinical and subclinical) subjects under survey. 
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Fig (5): Mean values of T3 (nmole/L) for euothyroid and hypothyroid 
(clinical and subclinical) subjects under survey. 
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Fig (6): Mean values of TSH (mIU/ml) for euthyroid and 
hypothyroid (clinical and subclinical) subjects under survey. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2 Thyroid function test status in the study group of Sudanese 
females: 
 
A total of one hundred and twenty females were selected to participate 
in the present study. 40 hypothyroid females, equal number fit the criteria for 
subclinical hypothyroidism cases, and the remaining 40 were euthyroid 
selected as controls. The mean of age for euothyroid about 32 years and 34 
years for hypothyroid subjects and about 44 for Sub clinical hypothyroid 
subjects (fig  7).  
 
 The mean level of serum T4 among euothyroid, hypothyroid and 
subclinical hypothyroid subjects were found to be 94.30, 18.4 and 89.7 
nmole/L respectively,  hypothyroid cases, showed significantly lower levels of 
T4, (P < 0.001), but subclinical hypothyroid subjects showed non significantly 
different level of T4 compared to the control (Table 6 Fig 8 and 9).   
 
Mean values for serum T3 among euothyroid, hypothyroid and sub 
clinical hypothyroid groups were found to be 1.96, 1.19 and 1.95 nmole/L 
respectively (Table 6 Fig 10 and 11). The euothyroid mean level of TSH, 
when determined in this study, was found to be (1.60+ 0.54 mIU/ml). 
Hypothyroid cases showed significantly higher levels compared to euothyroid 
(P < 0.001) with TSH mean about (49.6 mIU/ml). Among subjects with 
subclinical hypothyroidism, also there was a significantly higher TSH level 
compared to euothyroid subjects, (P < 0.005) (Table 6, Fig 12 and 13). 
 
  
 
 
 
  
Table (6): The levels of thyroid and thyroid stimulating 
hormones(Mean ± SD). 
 
• Mean within the same column having different small letters were 
significantly different. 
• ** (p < 0.001) and*(p < 0.005).  
 
 
 
 
 
 
 
 
 
 
Thyroid status Thyroxine T3       TSH 
Normal ranges 50-150 
 nmole/L 
0.80-3.0 
nmole/L 
     0.40-4.0 
mIU/ml 
Euothyroid subjects 94.30 a  ± 9.97 1.97 a ±0.46      1.60 a   ± 0.54
Hypothyroid subjects 18.4b ± 9.3 1.19a ± 0.79    49.6b**± 25.57
Subclinical 
hypothyroid subjects 
89.7 a  ± 11.39 1.9 a  ± 0.45      9.6 ± a*  2.69 
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Fig (7): Mean of age in years for euothyroid and hypothyroid 
(clinical and sub clinical) subjects under study 
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Fig (8): Mean values of T4 (nmole/L) of euothyroid hypothyroid and 
sub clinical hypothyroid subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig (9): Prevalence of T4 levels (nmole/L) among euothyroid, 
hypothyroid and sub clinical hypothyroid Sudanese Females  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig (10): T3 Levels (nmole/L) of euothyroid, hypothyroid and sub 
clinical hypothyroid subjects. 
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Fig (11): Prevalence of T3 levels (nmole/L) of euothyroid, 
hypothyroid and sub clinical hypothyroid subjects. 
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Fig (12): Mean levels of TSH (mIU/ml) of euothyroid, hypothyroid 
and sub clinical hypothyroid subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
Fig (13): The prevalence of TSH levels (mIU/ml) among Sudanese 
females under study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
3.3 Serum Lipid profiles results  
3.3.1 Triglycerides (TG) level among study groups 
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   The mean values of triglycerides were shown in figure 14 and table 7 
while the prevalence of triglycerides in the different three groups was 
shown in figure 15. Hypothyroidism showed significantly higher levels of 
TG (P < 0.001) compared to euothyroid subjects. Also there was 
statistically significant relationship between sub clinical hypothyroid 
cases and the euothyroid (P < 0.001), that sub clinical hypothyroid 
subjects showed high TG level.     
3.3.2 Total cholesterol level among study groups 
Total cholesterol levels were measured in the three groups using 
colorimetric method; the mean value of cholesterol was (172.68 + 31.0, 
194.5 ±40.51 227.6±59.88) mg/dl among euothyroid, sub clinical 
hypothyroid and hypothyroid subjects respectively,( as shown in figures 
16 and table 7) while the prevalence in the different groups was shown in 
figure 17. Hypothyroidism showed significantly higher levels of 
cholesterol (P < 0.001) compared to euothyroid subjects. However 
subjects with sub clinical hypothyroidism showed significantly high 
levels of cholesterol but less than of hypothyroidism (P < 0.05) compared 
to euothyroid subjects.  
3.3.3 High density lipoprotein cholesterol (HDL) level among study 
groups 
The fractions HDL- cholesterol was analyzed, results were 
represented in table 7 .Figure 18 shows the mean values of HDL-
cholesterol. While figure 19 shows the prevalence of HDL-cholesterol in 
the different groups of Sudanese females. There was no significant 
difference reported in the levels of HDL-C (P < 0.9). The mean of the 
serum levels among the controls and the sub clinical hypothyroid subjects 
were (52.05 + 11.5, 51.3±17.13 and 52.2±9.58) mg/dl respectively. 
3.3.4 Low density lipoproteins cholesterol (LDL) level among study 
groups 
The fractions LDL- cholesterol was analyzed, results were represented in 
table 7 .Figure 20 shows the mean values of LDL-cholesterol. While 
figure 21 shows the prevalence of LDL-cholesterol in the different groups 
of Sudanese females. Hypothyroidism showed significantly higher levels 
of LDL- cholesterol (P < 0.001) compared to euothyroid subjects. When 
LDL-C levels were considered, also there was statistically significant 
relationship between sub clinical hypothyroid cases and the controls (P < 
0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7 the results of triglycerides, total cholesterol, HDL- 
cholesterol and LDL- cholesterol expressed as mean ± SD among the 
euothyroid and hypothyroid and sub clinical hypothyroid subjects. 
 
Thyroid TG TC HDL-C LDL-C 
status Mean ±SD Mean ± SD Mean ±SD Mean ± SD 
Normal range 70-150 
 mg/dl 
150-240 
mg/dl 
30-70 
mg/dl 
 
70-130 
mg/dl 
 
Euthyroid 92.6a±48.91 172.7 a 
±31 
52.1 a 
±11.49 
104 a 
 ± 32.6 
Hypothyroid 189.2 b** 
±106.2 
 
227.6c ** 
± 
59.88 
51.3 a 
±17.13 
149.0 b ** 
± 
55.87 
Subclinical 
hypothyroid 
160.2 b * ±8.84 194.5 b * 
±40.51 
52.2 a ±9.58 116.3 a * 
± 
41.26 
 
** means the p value was significant between this group and control 
group at (P < 0.001).   
* means the p value was significant between this group and control group 
at (P < 0.05).   
• Means within the same column having different small letters were 
significantly different. 
 
 
 
 
 
 
Fig (14) Levels of Triglycerides (mg/dl) of the euothyroid, 
hypothyroid and sub clinical hypothyroid subjects. 
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Fig (15): Prevalence of TG among euothyroid, hypothyroid and sub 
clinical Sudanese females under study. 
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Fig (16): Mean values of Total cholesterol (mg/dl) of the euothyroid, 
hypothyroid and sub clinical hypothyroid subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
Fig (17): Prevalence of total cholesterol among subjects under study. 
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Fig (18): Values of HDL-Cholesterol (mg/dl) of the euothyroid, 
hypothyroid and sub clinical hypothyroid subjects. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 Fig (19): Prevalence of HDL-cholesterol among subjects under 
study. 
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Fig (20): Values of LDL-Cholesterol (mg/dl) of the euothyroid, 
hypothyroid and sub clinical hypothyroid subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 Fig (21): Prevalence of LDL-cholesterol among subjects under study. 
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DISCUSSION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Four 
Discussion 
4.1 The Survey: 
During the period from 1994 to 1996 about 15% of the Sudanese 
females referred to RIA laboratory of SAEC were found to be under 
treatment which is the same results found in males bearing in mind that 
87% of the referred patients were females and this is in a good agreement 
with what has been published by Sukkar et al., (2000) that all thyroid 
disturbances are more common in females than in males. 71.40% of the 
males were found to have euthyroid compared to 67.10% among the 
females who visited the laboratory in the same period. Those who had 
hypothyroid function among the males were found to represent 1.7% 
compared to 4.7% among the females. Sub- clinical hypothyroid was 
found to be 6.1% among the males and 6.2% among the females. To have 
a comprehensive study with regard to the study of the prevalence of these 
disorders; a detailed register should contain many parameters in addition 
to the data used to collect from the referred patients: that includes 
residence, tribe, family history of the disease or any endocrine disorder, 
treatment and any other informative data that can be used to reduce the 
risk factors and hence improve the quality of life for those who are 
considered to be under risk.   
4.2 Thyroid status:   
     This study was designed to compare the level of some serum lipid 
parameters (cholesterol, TG, LDL- cholesterol and HDL- cholesterol) in 
hypothyroid and subcilincal hypothyroid patients compared to euothyroid 
subjects. When T4 results were analyzed, the mean values were found to 
be 94.30, 18.4 and 89.7 nmole/L for euthyroid, hypothyroid and 
subclinical hypothyroid females respectively.   While the mean values for 
T3 were found to be 1.97, 1.19 and 1.95 for euthyroid, hypothyroid and 
subclinical hypothyroid females respectively. These findings were in 
agreement with levels reported by Series et al., (1988),who reported low 
plasma level of thyroxin (T4) less than or equal to 45 nmol/L in four 
individuals evident of hypothyroidism, as apart of a screening program 
for coronary heart disease risk factors in the general population in 
Scotland. 
     In this study subjects that considered as sub clinical hypothyroid cases 
have obviously elevated TSH levels and normal values for T3 and T4. 
Whereas these values were within normal range in euthyroid group and 
elevated TSH among hypothyroid groups. The mean values of TSH were 
found to be 1.60, 49.1 and 9.6 mIU/ml for euthyroid, hypothyroid and 
subclinical hypothyroid females respectively, go to table (6) page (44). 
These findings are explained by Adlin, (1998) who assumed that the 
elevation of TSH levels reflects the sensitivity of the hypothalamic-
pituitary axis to small decreases in circulating thyroid hormone. As the 
secretion of the thyroid gland decreased, the TSH level may rise above 
the upper limit of normal range.  
4.3 Serum lipids:         
  Triglycerides (TG) are the main storage lipid in adipose tissues and 
transported in the plasma via lipoproteins (Murray et al., 2000). In this 
study the serum levels of triglycerides (TG) for different groups were as 
follows:  among hypothyroid group, most cases showed high triglycerol 
levels, which reported mean level about 189.2±106.2 mg/dl compared to 
control group that reported mean level about 92.6 ±48.91, however, there 
is significant variation between the euothyroid and hypothyroid females 
(P < 0.001). In previous studies the plasma TG were found to be elevated 
in hypothyroidism (Nikkila and Kekki, 1972). On the other hand, it was 
demonstrated that triglycerides metabolism is disturbed due to thyroid 
hypo function but to smaller extent than that of plasma cholesterol (Brook 
and Marshal, 2001), also these findings agree with many authors who 
found this observation is not surprising as hypothyroidism is known to 
exert widespread effect on hepatic triglycerides assembly and secretion 
(Muller, 1984 and Barbagallo, 1995).  
          Among sub clinical hypothyroidism group slightly high TG level 
was found, whereas some cases remained within normal ranges, in 
comparison to euthyroid group that most of them were found within 
normal TG level, significant variation was found between euthyroid and 
subclinical hypothyroid (P < 0.001).  
          Total cholesterol levels among hypothyroid females were high with 
mean (227.6±59.88), compared to the control group, which represented 
normal cholesterol level (172.7±31). In case of sub clinical hypothyroid 
female cholesterol level was slightly elevated with mean about194.5 
±40.51. Highly significant variation was observed between euthyroid and 
hypothyroid females for total cholesterol with (P < 0.001); the same 
result was found between euthyroid and subclinical hypothyroid females. 
Since the plasma cholesterol level is decreased by thyroid hormones, 
which increase the number of LDL receptors in the liver according to 
Ganong (2001), these results are agreed with other findings by Kinlaw 
(1995), who assumed that an increased risk for atherosclerosis in sub 
clinical hypothyroidism is thought to be due to the elevated cholesterol 
levels and the same results were found by Ball et al., (1991) and 
Carantoni et al., (1997). 
    Low-density lipoprotein (LDL) cholesterol fraction in this study was 
high in hypothyroidism and sub clinical hypothyroid females compared to 
euothyroid group which registered no elevation in these fractions, Highly 
significant variation was observed between euothyroid and hypothyroid 
females for LDL- cholesterol with (P < 0.001), the same finding was 
observed between euothyroid and sub clinical hypothyroid females. Study 
done by Canaris et al., (2000) noted significant elevation of LDL-
cholesterol level in subjects with sub clinical hypothyroidism. The 
elevated LDL-cholesterol levels in hypothyroidism may occur as a result 
of increased cholesterol synthesis and absorption (Abrams and Grundy, 
1981) decreased hepatic lipase and lipoprotein lipase activities 
(Valdemarsson and Nilsson-Ehle, 1982), and defects in the receptor-
mediated catabolism of LDL (Chait et al., 1979 and Thompson et al., 
1981).  
      Findings in the present study clearly showed that patients with 
hypothyroidism, their serum levels of triglycerides, total cholesterol and 
LDL- cholesterol are elevated, patients with sub clinical hypothyroidism, 
not surprisingly, the same changes are present but are less marked and 
less consistent. It is well known that hypothyroidism exhibits a reduction 
in the synthesis of cholesterol and in LDL catabolism, whereas 
cholesterol reabsorption is unchanged or even enhanced (Williams, 
1997). The effect of sub clinical hypothyroidism on serum lipid levels 
and cardiovascular disease remain surrounded by controversy. However 
in the present study hypercholesterolemia was a common criterion among 
hypothyroid and sub clinical hypothyroid females.       
           The HDL-cholesterol levels were found to be within the normal 
ranges in all groups of this study, with no significant variation between 
the euothyroid and hypothyroid females and between the euothyroid and 
sub clinical hypothyroid females which means that there is no significant 
influence to the HDL-C levels. This also was found by Sasidharan, 
(1996).   
This pattern of lipid abnormalities, of course, is important because 
it is a risk factor for atherosclerotic cardiovascular disease. Some 
studiesdone by Arem and Patsch, (1990); Franklin et al., (1993) but not 
others, (Cooper et al.,1983) have shown a decrease in LDL-cholesterol 
and total cholesterol levels after treatment with levothyroxine.    
  It is generally well known and repeatedly published that patients with 
hypothyroidism and sub clinical hypothyroidism show increased levels of 
cholesterol. This is believed to be resulted from impaired metabolism due 
to a decreased thyroid function (Williams, 1997). The same results are 
found to be true for LDL-C and TG among the hypothyroid and sub 
clinical hypothyroid subjects in the present work.  
        In some studies the relation between TSH and total cholesterol or 
LDL-C is inconsistent. Moreover, Williams and Williams, (2004), in a 
population-based study, concluded that sub clinical hypothyroidism does 
not appear to be associated with abnormalities in serum cholesterol or TG 
levels when adjusted for confounding variables. A more controversial 
issue is whether sub clinical hypothyroidism poses an increased risk for 
atherosclerosis. In summary, both hypothyroidism and sub clinical 
hypothyroidism are associated with increased levels of TG, cholesterol 
and LDL compared to that in the euthyroid state.  
 
 
 
 
 
 
 
Conclusion 
 
  The present study is carried out to analyze the records of thyroid 
function test (TFT) statistically to know the average of thyroid gland 
hypo function for subjects referred to RIA laboratory of SAEC (1994-
1996) by using micro soft excel, and estimate the levels of some lipid 
profiles from blood samples of Sudanese females that are either suffering 
from clinical or sub clinical hypothyroid function.  
Subjects with sub clinical hypothyroidism showed higher serum 
levels of cholesterol, LDL, and TG which are significantly different from 
the euothyroid subjects. Unfortunately, records on the levels of the 
thyroid hormones in euothyroid subjects and cases of thyroid 
dysfunctions are lacking in Sudan. Also there is no any kind of studies 
that focus on changes in the plasma lipids profile associated with sub 
clinical hypothyroidism. 
Recommendations 
1- To the Endocrinology laboratories:  
a. To modify the registration form for the referred subjects to 
include tribe, original residence, family history of the 
disease, economical status. 
b. To make sure that age, sex and treatment are fully addressed. 
c. To make use of samples to conduct research in the 
biochemistry and physiology of human being after getting 
the permission. 
2- To do lipid profile testing for patients who have clinical or sub 
clinical hypo thyroid functions.  
3- A good filing system must be follow to facilitate the knowledge of 
the follow up of the thyroid disorders since Sudan was considered 
as endemic goiter area (Eltom et al., 1984) 
4- A network of researchers from the different laboratories should be 
connected to share the knowledge of the different disorders and 
research results.     
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